Malignant Liver Neoplasm clinical trials
10 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
- Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Malignant Liver Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.